NetworkNewsBreaks – Nkarta, Inc. (NASDAQ: NKTX) Featured in Mizuho Securities Research Report
Nkarta (NASDAQ: NKTX) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Nkarta and CRISPR Therapeutics (CRSP, not covered) announced a 50/50 collaboration to develop two NK cell therapies. One of these will target CD70 for indications including solid tumors and one is still TBD. They will also develop a combination NK+T cell therapy to target both innate and adaptive immunity. Additionally, Nkarta receives a license to use CRISPR technology to edit five gene targets in any of its own assets.”To request access to the full report, visit http://nnw.fm/SaZ9d About Nkarta, Inc.Nkarta is…







